Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PGNX - Progenics Pharmaceuticals Inc.

Previous close
4.1
0   0%

Share volume: 0
Last Updated: Fri 19 Jun 2020 06:00:00 AM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$4.10
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 8%
Dept financing 17%
Liquidity 23%
Performance 34%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$4.10
P/E Ratio 
N/A
DAY RANGE
$4.10 - $4.10
EPS 
-$0.77
52 WEEK RANGE
$1.89 - $6.37
52 WEEK CHANGE
-$18.00
MARKET CAP 
355.044 M
YIELD 
N/A
SHARES OUTSTANDING 
86.596 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,561,142
AVERAGE 30 VOLUME 
$1,918,553
Company detail
CEO: Mary Anne Heino
Region: US
Website: http://www.progenics.com
Employees: 105
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Recent news